Your session is about to expire
← Back to Search
Allogeneic Hematopoietic Stem Cell Transplantation for Blood Cancers
Study Summary
This trial is testing inotuzumab ozogamicin given with fludarabine phosphate, bendamustine hydrochloride, and rituximab before a donor stem cell transplant in treating patients with lymphoid malignancies.
- Blood Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 2 trial • 77 Patients • NCT01251575Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there precedents for this type of blood cell transplant surgery?
"Across the world, there are 1083 ongoing trials studying Allogeneic Hematopoietic Stem Cell Transplantation with 195 of those in Phase 3. Although many of these trials originated in Philadelphia, Pennsylvania, they are now being conducted in 24605 different locations."
What type of illnesses or injuries does Allogeneic Hematopoietic Stem Cell Transplantation help with?
"Allogeneic Hematopoietic Stem Cell Transplantation can not only be used to treat dermatitis, but also atopic conditions like multiple sclerosis. Additionally, it has shown efficacy in the treatment of b-cell lymphomas and polyangium."
How can I join this clinical research project?
"The patients who will be eligible for this trial must have hematologic neoplasms and be between the ages of 18-70. So far, 27 people have been accepted into the study."
How many people are total in this clinical study?
"Recruitment for this trial has ceased. The first posting was on October 29th, 2012 and the most recent edit was made on May 4th, 2022. However, there are 368 other studies currently recruiting patients with hematologic neoplasms and 1083 studies regarding Allogeneic Hematopoietic stem cell transplantation that are still looking for participants."
Are people over the age of 40 eligible to participate in this research project?
"This trial includes a broad age range of 18 to 70 years old, as specified in the inclusion criteria."
What is the end-goal of this clinical trial?
"The primary outcome of this trial is to assess the maximum-tolerated dose (MTD) of inotuzumab ozogamicin over a period of up to 30 days. Secondary outcomes include overall survival (OS), which will be estimated using Kaplan-Meier survival curves, and cumulative incidence of acute and chronic graft versus host disease (GVHD). The association between disease and clinical characteristics and the survival outcomes will be assessed using Cox proportional hazards regression methodology."
Can people with the relevant medical condition still enroll in this research project?
"The clinical trial in question is not actively recruiting patients according to the information found on clinicaltrials.gov. The trial was initially posted on 10/29/2012 and was last edited on 5/4/2022. Even though this particular study isn't looking for participants, there are 1451 other trials that are currently active."
Share this study with friends
Copy Link
Messenger